Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2020 01:30 ET | Source: Polyphor AG

Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadin

Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosisDevelopment program...
October 29, 2020 02:30 ET | Source: Polyphor AG

Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

ALLSCHWIL, Switzerland, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announces that it has completed recruitment in its FORTRESS Phase III study of balixafortide in metastatic...
October 14, 2020 01:30 ET | Source: Polyphor AG

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

ALLSCHWIL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), announced today that it has received a new and second non-dilutive funding award from CARB-X (Combating...
September 29, 2020 01:00 ET | Source: Polyphor AG

Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receipt of $15 Million Upfront Payment

ALLSCHWIL, Switzerland, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announced the closing of the previously announced exclusive licensing agreement with Fosun Pharma for...